eLearning module: Immunogenicity
In this expert authored eLearning module, Professor Huub Schellekens explains the concept of immunogenicity and how it affects the safety of biosimilars. This module also provides some considerations on how to interpret immunogenicity data in clinical practice.
This module will take up to 20 minutes to complete. An application for accreditation of this curriculum has been made to EACCME®. To claim your credits, please ensure you complete the evaluation form at the end of the module. Credits are only commensurate with completion of all of the designated modules.
Learning objectives
On completion of the eLearning module, you will be able to:
- Explain the factors that contribute to, and the consequences of, immunogenicity of biosimilars.
- Discuss the design and importance of immunogenicity assessments during the development of biosimilars.
Target audience
All medical oncologists, specialist nurses, and allied healthcare professionals working with patients for whom biosimilars may represent a treatment option.
r Huub Schellekens MD, PhD is emeritus professor of Pharmaceutical Biotechnology at Utrecht University in the Netherlands. He studied medicine at Erasmus University in Rotterdam, The Netherlands ( 1967-1973), where he also did his training in Medical Microbiology (1976-1980) and received his PhD. in 1980.